NCT04504942View on ClinicalTrials.gov

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

November 7, 2021

Study Completion Date

July 15, 2022

Conditions
Solid Tumor, Adult
Interventions
DRUG

Leronlimab

Drug: Leronlimab 525mg

Trial Locations (1)

94122

Quest Clinical Research, San Francisco

Sponsors

Lead Sponsor

CytoDyn, Inc.

Collaborators (1)

Amarex Clinical Research
All Listed Sponsors
collaborator

Amarex Clinical Research

OTHER

lead

CytoDyn, Inc.

INDUSTRY